What are the best steps in validating antibodies for use in therapeutics? How can researchers find the right antibody for new targets such as GPCRs? What is needed for fast and efficient development of anti-COVID-19 antibodies?
As common challenges in therapeutic antibody discovery are experienced across the field, companies are finding ways to innovate using new methods and technologies such as AI and machine learning.
The following pages present a collection of industry insights, exploring the latest approaches and technologies for therapeutic antibody discovery, alongside expert advice on tackling the key challenges along the way.
Jump to any article using the contents on the following page, or at any time using the Contents menu in the top left. There you can also download this eBook as a PDF.
Fully human antibody are the trend of therapeutic antibody. As of February 2021, the FDA has formally approved a cumulative total of 100 antibody drugs, of which 36 have been fully human antibody drugs.
GenScript ProBio provides a rapid solution to enable our clients to get fully human antibody sequences as fast as 1 month by combing Berkeley Lights BeaconTM single B cell screening platform with transgenic animals.
GenScript ProBio has established partnership with 3 transgenic animal platforms which are OmniAb® from Ligand in US, Alloy ATX-GKTM Mouse in US and CAMouseTM from CAMAB in China. We have been authorized to use their animals to provide antibody discovery service.
Moreover, GenScript ProBio offers a limited time 25% off discount for single B cell screening projects using transgenic animals.
For more info, please refer to https://genscriptprobio.com/add-transgenic-mouse.html
1. Rapid Discovery of Antibodies to Integral Membrane Proteins: A CXCR5 Seven Transmembrane Receptor Case Study
This article explores the latest work on creating anti-GPCR therapeutics by Distributed Bio, as presented at the Antibody Engineering & Therapeutics conference.
2. GenScript ProBio’s ProSpeed™ accelerate anti-COVID-19 neutralizing antibody leads discovery with sub-nM IC50
This whitepaper by Genscript explains how its leading single B cell screening platform has been used to accelerate discovery of neutralizing antibodies for treatment, prophylaxis, and detection of SARS-CoV-2.
3. Human Monoclonal Antibodies for SARS-CoV-2
We look back at the highlights of an insightful presentation on single cell technologies for the isolation of human monoclonals, the molecular basis for SARS-CoV-2 neutralization, and antibody synergistic exploration by James Crowe Jr., Director at Vanderbilt Vaccine Center.
4. TARGATT™ Unique Technology for Antibody Discovery and Screening
In this whitepaper, Applied StemCell presents case studies in which its TARGATT™ gene editing technology enabled an irreversible, site-specific gene insertion at a safe-harbor locus.
